Literature DB >> 9218124

Oncoprotein signalling and mitosis.

A D Laird1, D Shalloway.   

Abstract

Studies of the roles of oncoproteins in cell cycle progression have concentrated on G1 because transformation is frequently associated with loss of G1 checkpoint control. However, it has become evident that G2 and mitotic checkpoints are often compromised in transformed cells and that many tumour suppressor proteins and oncoprotein kinases regulate and/or are activated in G2 and M. Disruption of p53 and ATM tumour suppressor protein functions can eliminate G2 and M checkpoints. The Src family kinases are activated in mitosis and collectively play an indispensable role in progression through G2/M. In addition, evidence suggests that Mos and elements of the Ras/Raf/MAPK cascade are also active in mitosis and appear likely to regulate G2 and/or M. Potential targets of these kinases include likely regulators of gene expression and microtubule dynamics such as Sam68 and Oncoprotein 18/stathmin. The ability of some oncoproteins to perturb orderly progression through both G1 and/or S and G2 and/or M is probably important for transformation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218124     DOI: 10.1016/s0898-6568(96)00176-3

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  15 in total

1.  Active erk regulates microtubule stability in H-ras-transformed cells.

Authors:  R E Harrison; E A Turley
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

2.  The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.

Authors:  Yi Zhan; George J Counelis; Donald M O'Rourke
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

3.  Stress activated p38 MAPK regulates cell cycle via AP-1 factors in areca extract exposed human lung epithelial cells.

Authors:  Rashmi Nagesh; K M Kiran Kumar; M Naveen Kumar; Rajeshwari H Patil; S Chidananda Sharma
Journal:  Cytotechnology       Date:  2019-02-02       Impact factor: 2.058

4.  Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts.

Authors:  J H Wright; E Munar; D R Jameson; P R Andreassen; R L Margolis; R Seger; E G Krebs
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells.

Authors:  J S Park; S Carter; D B Reardon; R Schmidt-Ullrich; P Dent; P B Fisher
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

6.  Lyn is activated during late G1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells.

Authors:  S Mou; D Linnekin
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

7.  Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells.

Authors:  K Fukuoka; J Usuda; Y Iwamoto; H Fukumoto; T Nakamura; T Yoneda; N Narita; N Saijo; K Nishio
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

8.  Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression.

Authors:  Rui Wang; Ke Dong; Fang Lin; Xi Wang; Ping Gao; San-Hua Wei; Shi-Yin Cheng; Hui-Zhong Zhang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

9.  Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.

Authors:  Michele Navarra; Marilena Celano; Jessica Maiuolo; Silvia Schenone; Maurizio Botta; Adriano Angelucci; Placido Bramanti; Diego Russo
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

10.  Toggle switches, pulses and oscillations are intrinsic properties of the Src activation/deactivation cycle.

Authors:  Nikolai P Kaimachnikov; Boris N Kholodenko
Journal:  FEBS J       Date:  2009-08       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.